ValuEngine downgraded shares of Cellectis (NASDAQ:CLLS) from a buy rating to a hold rating in a research report sent to investors on Friday.
A number of other analysts also recently issued reports on CLLS. BidaskClub raised shares of Cellectis from a sell rating to a hold rating in a report on Saturday, October 6th. Zacks Investment Research raised shares of Cellectis from a hold rating to a buy rating and set a $25.00 price objective for the company in a report on Friday. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $48.00.
Shares of CLLS stock traded down $0.51 during midday trading on Friday, hitting $22.00. 429,287 shares of the company were exchanged, compared to its average volume of 122,450. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -7.91 and a beta of 1.76. Cellectis has a 52 week low of $21.29 and a 52 week high of $38.85.
A number of hedge funds and other institutional investors have recently bought and sold shares of CLLS. Harel Insurance Investments & Financial Services Ltd. bought a new stake in Cellectis in the 3rd quarter valued at about $129,000. Commonwealth Equity Services LLC bought a new stake in Cellectis in the 2nd quarter valued at about $237,000. UBS Group AG boosted its holdings in Cellectis by 143.1% in the 1st quarter. UBS Group AG now owns 15,383 shares of the biotechnology company’s stock valued at $485,000 after purchasing an additional 9,054 shares during the period. Prosight Management LP bought a new stake in Cellectis in the 2nd quarter valued at about $548,000. Finally, Adalta Capital Management LLC bought a new stake in Cellectis in the 2nd quarter valued at about $620,000. 27.07% of the stock is owned by hedge funds and other institutional investors.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Read More: S&P 500 Index
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.